About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Nos2
nitric oxide synthase 2, inducible
MGI:97361
103 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Adh5tm1Stam/Adh5tm1Stam
Nos2tm1Lau/Nos2tm1Lau
involves: 129 * 129P2/OlaHsd 		normal mortality/aging J:173666
Agertm1.1Hyam/Ager+
Tg(Ins2-Nos2)40Okam/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA/2 		abnormal renal glomerulus morphology J:116040
glomerulosclerosis J:116040
hyperglycemia J:116040
Agertm1.1Hyam/Agertm1.1Hyam
Tg(Ins2-Nos2)40Okam/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA/2 		abnormal kidney size J:116040
abnormal renal glomerulus morphology J:116040
albuminuria J:116040
decreased circulating creatinine level J:116040
glomerulosclerosis J:116040
hyperglycemia J:116040
ApcMin/Apc+
Nos2tm1Lau/Nos2+
B6.Cg-Nos2tm1Lau ApcMin 		decreased tumor growth/size J:73152
decreased tumor incidence J:73152
ApcMin/Apc+
Nos2tm1Lau/Nos2tm1Lau
B6.Cg-Nos2tm1Lau ApcMin 		decreased tumor growth/size J:73152
decreased tumor incidence J:73152
ApcMin/Apc+
Msh2tm1Mak/Msh2+
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		intestine polyps J:200824
ApcMin/Apc+
Msh2tm1Mak/Msh2tm1Mak
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		intestine polyps J:200824
Apoetm1Unc/Apoetm1Unc
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		atherosclerotic lesions J:64566
decreased cholesterol level J:64566
normal homeostasis/metabolism phenotype J:64566
increased body weight J:64566
Faslpr/Faslpr
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129S7/SvEvBrd * MRL 		abnormal blood homeostasis J:42666
abnormal immunoglobulin level J:42666
abnormal urine homeostasis J:42666
decreased IgG level J:42666
decreased IgM level J:42666
decreased urine nitrite level J:42666
normal immune system phenotype J:42666
Il10tm1Cgn/Il10tm1Cgn
Nos2tm1Lau/Nos2tm1Lau
involves: 129P2/OlaHsd * C57BL/6 		increased myocardial infarct size J:70292
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Lau/Nos2tm1Lau
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J 		prenatal lethality, incomplete penetrance J:83112
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129S4/SvJae * 129S7/SvEvBrd 		decreased survivor rate J:100308
decreased urine osmolality J:100308
decreased urine sodium level J:100308
increased blood osmolality J:100308
increased blood urea nitrogen level J:100308
polydipsia J:100308
polyuria J:100308
premature death J:100308
reduced fertility J:100308
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
involves: 129S4/SvJae * 129S7/SvEvBrd 		abnormal bone mineralization J:150159
abnormal bone structure J:150159
abnormal coronary artery morphology J:100308
abnormal glomerular capillary thrombosis J:100308
abnormal kidney physiology J:100308
abnormal nitric oxide homeostasis J:100308
abnormal osteoclast physiology J:150159
abnormal renal glomerulus morphology J:100308
abnormal skeleton physiology J:150159
abnormal trabecular bone morphology J:150159
congestive heart failure J:100308
decreased heart rate J:100308
decreased survivor rate J:100308
decreased urine osmolality J:100308
decreased urine sodium level J:100308
dehydration J:100308
enlarged stomach J:100308
glomerulosclerosis J:100308
hypertension J:100308
increased blood osmolality J:100308
increased blood urea nitrogen level J:100308
increased bone mineral density J:150159
increased circulating alkaline phosphatase level J:150159
increased circulating creatinine level J:100308
increased osteoclast cell number J:150159
increased prostaglandin level J:100308
increased renal tubule apoptosis J:100308
increased systemic arterial blood pressure J:100308
increased systemic arterial systolic blood pressure J:100308
liver vascular congestion J:100308
polydipsia J:100308
polyuria J:100308
premature death J:100308
pulmonary vascular congestion J:100308
pyloric sphincter hypertrophy J:100308
reduced fertility J:100308
renal tubular necrosis J:100308
visceral vascular congestion J:100308
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		abnormal cardiovascular system morphology J:155090
abnormal cardiovascular system physiology J:155090
abnormal circulating glucose level J:155090
abnormal vascular endothelial cell physiology J:155090
abnormal vascular wound healing J:155090
arteriosclerosis J:155090
decreased adiponectin level J:155090
hypertension J:155090
increased circulating LDL cholesterol level J:155090
increased circulating triglyceride level J:155090
increased white adipose tissue amount J:155090
perivascular fibrosis J:155090
premature death J:155090
thick ventricular wall J:155090
Nos2tm1Lau/Nos2tm1Lau
Nos3tm1Unc/Nos3tm1Unc
B6.129P2-Nos3tm1Unc Nos2tm1Lau 		prenatal lethality, incomplete penetrance J:83112
Nos2tm1Lau/Nos2tm1Lau
Tg(APPSWE)2576Kha/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal hippocampus CA3 region morphology J:143551
abnormal long-term spatial reference memory J:143551
abnormal subiculum morphology J:143551
amyloid beta deposits J:112919, J:143551
decreased neuron number J:143551
loss of hippocampal neurons J:143551
neuron degeneration J:112919
Nos2tm1Lau/Nos2tm1Lau
Tg(MMTV-PyVT)634Mul/0
B6.Cg-Nos2tm1Lau Tg(MMTV-PyVT)634Mul 		abnormal tumor morphology J:121391
decreased tumor incidence J:121391
increased tumor latency J:84218, J:121391
Nos2tm1Lau/Nos2tm1Lau
Tg(MMTV-PyVT)634Mul/0
FVB.Cg-Nos2tm1Lau Tg(MMTV-PyVT)634Mul 		decreased tumor latency J:121391
increased tumor growth/size J:121391
increased tumor incidence J:121391
Nos2tm1Lau/Nos2tm1Lau
Tg(RHO-VEGFA)V-6Camp/0
involves: 129P2/OlaHsd * C57BL/6J 		abnormal angiogenesis J:106207
Nos2tm1Lau/Nos2tm1Lau
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: C57BL/6 		abnormal brain interneuron morphology J:143551
abnormal hippocampus CA3 region morphology J:132221, J:143551
abnormal spatial reference memory J:132221
amyloid beta deposits J:132221, J:143551
decreased neuron number J:143551
decreased subiculum size J:132221, J:143551
hippocampal neuron degeneration J:132221
increased neuron apoptosis J:132221
neurodegeneration J:132221
tau protein deposits J:132221
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
involves: 129S4/SvJae * 129S7/SvEvBrd 		decreased heart rate J:100308
decreased survivor rate J:100308
decreased urine osmolality J:100308
decreased urine sodium level J:100308
increased blood osmolality J:100308
increased blood urea nitrogen level J:100308
increased systemic arterial systolic blood pressure J:100308
polydipsia J:100308
polyuria J:100308
premature death J:100308
reduced fertility J:100308
Nos2tm1Mrl/Nos2tm1Mrl
Tg(Myh6-Tnf)1.6Amf/?
involves: 129S7/SvEvBrd * C57BL/6 * FVB 		abnormal atrioventricular node conduction J:109732
abnormal cardiac muscle contractility J:109732
abnormal heart electrocardiography waveform feature J:109732
abnormal heart ventricle pressure J:109732
abnormal myocardial fiber physiology J:109732
decreased cardiac muscle contractility J:109732
decreased heart rate J:109732
irregular heartbeat J:109732
Tg(Ins2-Nos2)40Okam/0
Tg(Kdr-AGER)102Hyam/0
involves: C57BL/6J * CBA/J * CD-1 * DBA/2 		abnormal nephron morphology J:70495
albuminuria J:70495
arteriosclerosis J:70495
atherosclerotic lesions J:70495
expanded mesangial matrix J:70495
glomerulosclerosis J:70495
hyperglycemia J:70495
increased circulating creatinine level J:70495
increased kidney cell proliferation J:70495
increased kidney weight J:70495
renal glomerulus hypertrophy J:70495
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory